Neuropeptide FF receptors as therapeutic targets

Drugs of the Future

Volumn 31, Issue 7, 2006, Pages 603-609

  Simonin, Frédéric ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; G PROTEIN COUPLED RECEPTOR; MORPHINE; NALOXONE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NARCOTIC ANALGESIC AGENT; NEUROPEPTIDE FF; NEUROPEPTIDE FF RECEPTOR; NEUROPEPTIDE FF RECEPTOR ANTAGONIST; NEUROPEPTIDE RECEPTOR; OPIATE AGONIST; OPIATE RECEPTOR; RECEPTOR BLOCKING AGENT; RF 9; UNCLASSIFIED DRUG;

ALLODYNIA; AMINO ACID SEQUENCE; CANCER PAIN; CARBOXY TERMINAL SEQUENCE; CHRONIC PAIN; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERANCE; FEEDING BEHAVIOR; HEART FUNCTION; HUMAN; HYPERALGESIA; INSULIN RELEASE; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; POSTOPERATIVE PAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33750094911     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.07.1007143     Document Type: Review

References (75)

1. Fredriksson, R., Schioth, H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 2005, 67: 1414-25.
2. Vassilatis, D.K., Hohmann, J.G., Zeng, H. et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA 2003, 100: 4903-8.
3. Schlyer, S., Horuk, R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today 2006, 11: 481-93.
4. Hopkins, A.L., Groom, C.R. The druggable genome. Nat Rev Drug Discov 2002, 1: 727-30.
5. Civelli, O. GPCR deorphanizations: The novel, the known and the unexpected transmitters. Trends Pharmacol Sci 2005, 26: 15-9.
6. Price, D.A., Greenberg, M.J. Structure of a molluscan cardioexcitatory neuropeptide. Science 1977, 197: 670-1.
7. Li, C., Kim, K., Nelson, L.S. FMRFamide-related neuropeptide gene family in Caenorhabditis elegans. Brain Res 1999, 848: 26-34.
8. Yang, H.Y., Fratta, W., Majane, E.A., Costa, E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA 1985, 82: 7757-61.
9. Perry, S.J., Yi-Kung Huang, E., Cronk, D. et al. A human gene encoding morphine modulating peptides related to NPFF and FMRFamide. FEBS Lett 1997, 409: 426-30.
10. Bonini, J.A., Jones, K.A., Adham, N. et al. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem 2000, 275: 39324-31.
11. Elshourbagy, N.A., Ames, R.S., Fitzgerald, L.R. et al. Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J Biol Chem 2000, 275: 25965-71.
12. Hinuma, S., Shintani, Y., Fukusumi, S. et al. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol 2000, 2: 703-8.
13. Liu, Q., Guan, X.M., Martin, W.J. et al. Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J Biol Chem 2001, 276: 36961-9.
14. Lingueglia, E., Deval, E., Lazdunski, M. FMRFamide-gated sodium channel and ASIC channels: A new class of ionotropic receptors for FMRFamide and related peptides. Peptides 2006, 27: 1138-52.
15. Hinuma, S., Habata, Y., Fujii, R. et al. A prolactin-releasing peptide in the brain. Nature 1998, 393: 272-6.
16. Kotani, M., Detheux, M., Vandenbogaerde, A. et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem 2001, 276: 34631-6.
17. Ohtaki, T., Shintani, Y., Honda, S. et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001, 411: 613-7.
18. Chartrel, N., Dujardin, C., Anouar, Y. et al. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc Natl Acad Sci USA 2003, 100: 15247-52.
19. Fukusumi, S., Yoshida, H., Fujii, R. et al. A new peptidic ligand and its receptor regulating adrenal function in rats. J Biol Chem 2003, 278: 46387-95.
20. Jiang, Y., Luo, L., Gustafson, E.L. et al. Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155. J Biol Chem 2003, 278: 27652-7.
21. Panula, P., Aarnisalo, A.A., Wasowicz, K. Neuropeptide FF, a mammalian neuropeptide with multiple functions. Prog Neurobiol 1996, 48: 461-87.
22. Zeng, Z., McDonald, T.P., Wang, R., Liu, Q., Austin, C.P. Neuropeptide FF receptor 2 (NPFF2) is localized to pain-processing regions in the primate spinal cord and the lower level of the medulla oblongata. J Chem Neuroanat 2003, 25: 269-78.
23. 125I]EYF: A new high affinity radioligand to neuropeptide FF receptors. Peptides 2001, 22: 623-9.
24. 125I]EYF as selective radioligands. Neuroscience 2002, 115: 349-61.
25. Gouarderes, C., Puget, A., Zajac, J.M. Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig, and marmoset monkey brains: A comparative autoradiographic study. Synapse 2004, 51: 249-69.
26. Gerald, C.P.G., Jones, K., Bonini, J.A., Borowsky, B. (Synaptic Pharma Corp.). DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof. WO 0018438.
27. Yang, H.Y., Iadarola, M.J. Activation of spinal neuropeptide FF and the neuropeptide FF receptor 2 during inflammatory hyperalgesia in rats. Neuroscience 2003, 118: 179-87.
28. Vilim, F.S., Aarnisalo, A.A., Nieminen, M.L. et al. Gene for pain modulatory neuropeptide NPFF: Induction in spinal cord by noxious stimuli. Mol Pharmacol 1999, 55: 804-11.
29. Stewart, W.F., Ricci, J.A., Chee, E., Morganstein, D., Lipton, R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA - J Am Med Assoc 2003, 290: 2443-54.
30. Kieffer, B.L., Evans, C.J. Opioid tolerance - In search of the holy grail. Cell 2002, 108: 587-90.
31. Rothman, R.B. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 1992, 12: 129-38.
32. Ossipov, M.H., Lai, J., Vanderah, T.W., Porreca, F. Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sci 2003, 73: 783-800.
33. Simonnet, G., Rivat, C. Opioid-induced hyperalgesia: Abnormal or normal pain? Neuroreport 2003, 14: 1-7.
34. Mao, J., Price, D.D., Mayer, D.J. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995, 62: 259-74.
35. Larcher, A., Laulin, J.P., Celerier, E., Le Moal, M., Simonnet, G. Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience 1998, 84: 583-9.
36. Celerier, E., Rivat, C., Jun, Y. et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology 2000, 92: 465-72.
37. Celerier, E., Laulin, J.P., Corcuff, J.B., Le Moal, M., Simonnet, G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J Neurosci 2001, 21: 4074-80.
38. Mao, J. Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain 2002, 100: 213-17.
39. Angst, M.S., Clark, J.D. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology 2006, 104: 570-87.
40. White, J.M. Pleasure into pain: The consequences of long-term opioid use. Addict Behav 2004, 29: 1311-24.
41. Roumy, M., Zajac, J.M. Neuropeptide FF, pain and analgesia. Eur J Pharmacol 1998, 345: 1-11.
42. McNally, G.P. Pain facilitatory circuits in the mammalian central nervous system: Their behavioral significance and role in morphine analgesic tolerance. Neurosci Biobehav Rev 1999, 23: 1059-78.
43. Panula, P., Kalso, E., Nieminen, M., Kontinen, V.K., Brandt, A., Pertovaara, A. Neuropeptide FF and modulation of pain. Brain Res 1999, 848: 191-6.
44. Mollereau, C., Roumy, M., Zajac, J.M. Opioid-modulating peptides: Mechanisms of action. Curr Top Med Chem 2005, 5: 341-55.
45. Yang, H.Y., Fratta, W., Majane, E.A., Costa, E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA 1985, 82: 7757-61.
46. Oberling, P., Stinus, L., Le Moal, M., Simonnet, G. Biphasic effect on nociception and antiopiate activity of the neuropeptide FF (FLFQPQRFamide) in the rat. Peptides 1993, 14: 919-24.
47. Devillers, J.P., Boisserie, F., Laulin, J.P., Larcher, A., Simonnet, G. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res 1995, 700: 173-81.
48. Stinus, L., Allard, M., Gold, L., Simonnet, G. Changes in CNS neuropeptide FF-like material, pain sensitivity, and opiate dependence following chronic morphine treatment. Peptides 1995, 16: 1235-41.
49. Lake, J.R., Hammond, M.V., Shaddox, R.C., Hunsicker, L.M., Yang, H.Y., Malin, D.H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 1991, 132: 29-32.
50. 2-like mammalian octapeptide: Possible role in opiate dependence and abstinence. Peptides 1990, 11: 969-72.
51. 2]deltorphin-I. Synapse 1993, 13: 231-40.
52. Simonin, F., Schmitt, M., Laulin, J.-P. et al. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA 2006, 103: 466-71.
53. Nystedt, J.M., Lemberg, K., Lintunen, M. et al. Pain-and morphine-associated transcriptional regulation of neuropeptide FF and the G-protein-coupled NPFF2 receptor gene. Neurobiol Dis 2004, 16: 254-62.
54. Xu, M., Kontinen, V.K., Panula, P., Kalso, E. Effects of (1DMe)NPYF, a synthetic neuropeptide FF analogue, in different pain models. Peptides 1999, 20: 1071-7.
55. Altier, N., Dray, A., Menard, D., and Henry, J.L. Neuropeptide FF attenuates allodynia in models of chronic inflammation and neuropathy following intrathecal or intracerebroventricular administration. Eur J Pharmacol 2000, 407: 245-55.
56. Wei, H., Panula, P., Pertovaara, A. Modulation of pain by [1DMe]NPYF, a stable analogue of neuropeptide FF, in neuropathic rats. Brain Res 2001, 900: 234-43.
57. 2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 1990, 11: 277-80.
58. Malin, D.H., Lake, J.R., Arcangeli, K.R. et al. Subcutaneous injection of an analog of neuropeptide FF precipitates morphine abstinence syndrome. Life Sci 1993, 53: PL261-6.
59. Gelot, A., Frances, B., Gicquel, S., Zajac, J.M. Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur J Pharmacol 1998, 358: 203-6.
60. Huang, E.Y., Li, J.Y., Wong, C.H., Tan, P.P., Chen, J.C. Dansyl-PQRamide, a possible neuropeptide FF receptor antagonist, induces conditioned place preference. Peptides 2002, 23: 489-96.
61. Dockray, G.J. The expanding family of -RFamide peptides and their effects on feeding behaviour. Exp Physiol 2004, 89: 229-35.
62. Murase, T., Arima, H., Kondo, K., Oiso, Y. Neuropeptide FF reduces food intake in rats. Peptides 1996, 17: 353-4.
63. Sunter, D., Hewson, A.K., Lynam, S., Dickson, S.L. Intracerebroventricular injection of neuropeptide FF, an opioid modulating neuropeptide, acutely reduces food intake and stimulates water intake in the rat. Neurosci Lett 2001, 313: 145-8.
64. Nicklous, D.M., Simansky, K.J. Neuropeptide FF exerts pro- and anti-opioid actions in the parabrachial nucleus to modulate food intake. Am J Physiol Regul Integr Comp Physiol 2003, 285: R1046-54.
65. 2 antiserum. Neuropeptides 1987, 10: 37-42.
66. Allard, M., Labrouche, S., Nosjean, A., Laguzzi, R. Mechanisms underlying the cardiovascular responses to peripheral administration of NPFF in the rat. J Pharmacol Exp Ther 1995, 274: 577-83.
67. Jhamandas, J.H., Mactavish, D. Central administration of neuropeptide FF (NPFF) causes increased neuronal activation and up-regulation of NPFF gene expression in the rat brainstem. J Comp Neurol 2002, 447: 300-7.
68. Jhamandas, J.H., MacTavish, D. Central administration of neuropeptide FF causes activation of oxytocin paraventricular hypothalamic neurones that project to the brainstem. J Neuroendocrinol 2003, 15: 24-32.
69. Schmidt, W.E., Binder, G., Creutzfeldt, W. Potent inhibition of insulin secretion from pancreatic islets by two novel neuropeptides, MMP-1 and MMP-2. Acta Endocrinol (Copenhagen) 1989, 120: 8.
70. Fehmann, H.C., McGregor, G., Weber, V. et al. The effects of two FMRFamide related peptides (A-18-F-amide and F-8-F-amide; 'morphine modulating peptides') on the endocrine and exocrine rat pancreas. Neuropeptides 1990, 17: 87-92.
71. Masui, T., Doi, R., Mori, T. et al. Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun 2004, 315: 85-92.
72. Gicquel, S., Mazarguil, H., Allard, M., Simonnet, G., Zajac, J.M. Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. Eur J Pharmacol 1992, 222: 61-7.
73. Payza, K., Akar, C.A., Yang, H.Y. Neuropeptide FF receptors: Structure-activity relationship and effect of morphine. J Pharmacol Exp Ther 1993, 267: 88-94.
74. Mazarguil, H., Gouarderes, C., Tafani, J.A. et al. Structure-activity relationships of neuropeptide FF: Role of C-terminal regions. Peptides 2001, 22: 1471-8.
75. Vyas, N., Mollereau, C., Cheve, G., McCurdy, C.R. Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives. Peptides 2006, 27: 990-6.